The Health Insurance Review & Assessment Service’s reevaluations of premiums applied to listed drugs are being finalized.

On the 28th, HIRA held a post-marketing drug management subcommittee meeting to finalize its decision on the items for which the premiums would be terminated (products for price ceiling recalculation) according to the reorganized drug premium pricing system.

The subcommittee meeting was held to review items that companies submitted objections to, among candidates for reevaluation that was first selected at the Drug Reimbursement Evaluation Committee’s meeting on April 8th.

The specific number of items that would undergo re-evaluation will be di